Bill St. John - Vice President IP Strategy

Leadership Team

Bill St John is experienced in strategic intellectual property protection, licensing, university-industry relationships, corporate partnerships, strategic planning, due diligence, venture financing, corporate development and management of diverse teams and operations. Over the past 25 years, he has started and managed five (5) successful technology companies based on technology licensed or developed at university or government laboratories. His experience is unique in that each of these ventures utilized very diverse technologies, and targeted different industries. Each company utilized multi-discipline scientific teams. Exit strategies for these ventures included public markets, merger and acquisition.

Most recently, Mr. St. John served as CEO of InCode BioPharmaceutics, Inc. InCode is engaged in new drug development using cloning technologies. As CEO, he completed 3 rounds of venture funding and positioned the company for clinical trials of its drug candidates.

Prior to InCode, Mr. St. John served as CEO of Scolr Parma/ Nutraceutix, Inc., taking the company public and increasing its stock value three-fold. Scolr developed controlled delivery drug dosage forms using advanced polymer chemistry. The Nutraceutix division operated a tablet and formulation plant.

From 1984 – 1989 Mr. St. John served as President and COB for Ecova Environmental, Inc. Ecova applied biotechnology, infrared physics and chemical engineering to the large-scale remediation of superfund Sites. Ecova developed the basis for the majority of bioremediation technology in use today. The company was sold to Amoco oil in 1989.

From 1983 – 1998 Mr. St. John served as President and COB for BioTechniques Laboratories (BTL), Inc. BTL developed and manufactured veterinary & agricultural bio-products, sponsoring research in 20 universities and government labs. BTL achieved positive cash flow in its second year of operations.

Mr. St. John holds a BS from Seattle University and an MS from Ohio State University. He currently serves on the Boards of InCode BioPharmaceutics, Inc.